Search results
Results from the WOW.Com Content Network
In obstructive lung disease, the FEV1 is reduced due to an obstruction of air escaping from the lungs. Thus, the FEV1/FVC ratio will be reduced. [4] More specifically, according to the National Institute for Clinical Excellence, the diagnosis of COPD is made when the FEV 1 /FVC ratio is less than 0.7 or [8] the FEV 1 is less than 75% of predicted; [9] however, other authoritative bodies have ...
A derived value of FEV1 is FEV1% predicted (FEV1%), which is defined as FEV1 of the patient divided by the average FEV1 in the population for any person of the same age, height, gender, and race. [ medical citation needed ]
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
At week 8, the people on treatment with ivacaftor experienced an average absolute improvement in FEV1 of 13.8%, but there was a strong dependence of the efficacy on the exact mutation that a patient had. The detailed data for different mutation types is shown in the U.S. package insert. [3]
In obstructive lung disease however, the FEV1/FVC is less than 0.7, indicating that FEV1 is significantly reduced when compared to the total expired volume. This indicates that the FVC is also reduced, but not by the same ratio as FEV1. [8] One definition requires a total lung capacity which is 80% or less of the expected value. [9]
On average, there are approximately 100,000 hair follicles on the human head. Despite this, hair loss happens to everyone. Each day, we shed between 50 and 80 hairs naturally.
You've heard it a million times: Eat fewer calories, lose weight. But what if you're in a calorie deficit—consuming fewer calories than you're burning—and still not losing?
The list price of a year's treatment in the US is US$322,000 [44] (formerly US$311,000). [45] However, a 2020 report by Institute for Clinical and Economic Review found that the price has made the treatment not cost effective and that "an appropriate health-benefit price would range from $67,900–$85,500 per year". [46] [47]